The global pharmaceutical industry experienced 0% rise in patent filings in Q4 2023 compared with the previous quarter. The total number of grants dropped by 5%, resulting in overall patent publications increasing by 0.7%, according to GlobalData’s Patent Analytics. GlobalData’s databook Pharma: Patents Trends Q4 2023 offers comprehensive insights into patenting trends, major players’ strategies, and geographical focus in the sector over the last three years. Buy the databook here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Pharma: Patents Trends Q4 2023

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

Notably, the number of patent applications in the pharmaceutical industry was 65,126 in Q4 2023, versus 64,672 in the prior quarter. Filings were down 1% year-on-year and increase 0% quarter-on-quarter. This compares to a 1% year-on-year increase in patent grants and 0% rise in quarter-on-quarter.

The top five companies accounted for 3% of patenting activity

Analysis of patenting activity by companies shows that the largest number of patents filed over the last quarter was by F. Hoffmann-La Roche with 523, followed by Zhejiang University with 426 and Johnson & Johnson with 378.

Patenting activity was driven by China with a 38% share of total patent filings

The largest share of patent filings in the pharmaceutical industry in Q4 2023 was in China with 38%, followed by the US (14%) and Japan (7%). The share represented by China was 1% lower than the 40% share it accounted for in Q3 2023.

For further understanding of GlobalData's Pharma: Patents Trends Q4 2023, buy the databook here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.